Strategic Partnerships MSKCC actively engages in collaborations with industry partners, as seen in the July 2026 Akeso collaboration to advance a Phase II study. This signals openness to co-development and clinical trial partnerships that could open doors for biotech suppliers, CRO services, and research technology providers.

Capital Expansion MSKCC is investing in a new high-profile inpatient pavilion with a $2.3B budget in Manhattan, signaling ongoing capital projects and long-term facility modernization. This creates opportunities for suppliers in construction, clinical equipment, IT infrastructure, and facility management services.

Tech & Data Use The tech stack shows reliance on enterprise tools (TOGAF, Azure/EC2, content platforms, data and fundraising systems). This indicates potential needs for enterprise IT services, cybersecurity, data analytics, translational research platforms, and donor management solutions.

Clinical Innovation MSKCC leadership in CAR T therapy research and translational science points to ongoing needs for specialized research systems, bioreactor and cell therapy manufacturing support, and partnerships with biotech vendors for therapeutic development and GMP-grade scaling.

Donor & Stewardship Significant funding and donor engagement tools imply opportunities to offer fundraising platforms, donor analytics, CRM integration, and philanthropic marketing services aligned with MSKCC’s mission and expansive fundraising activities.